The healthcare sector in Brazil remains one of the strongest investment themes for both local and foreign investors. The fundamentals are biological and demographic: a rapidly aging population, growing structural demand, and a market that, despite recent major shifts, remains fragmented into various niches. However, the mergers and acquisitions (M&A) landscape has reached a new level of sophistication.
The success of these transactions now depends on variables that do not always appear in initial spreadsheets, revealing themselves only in the heat of negotiations or, more dangerously, after the deal closes. For those structuring these deals, the competitive edge has shifted from simply identifying assets to the ability to anticipate risks that continue to be underestimated.
With news from Anvisa and ANS, JOTA PRO Saúde delivers predictability and transparency for companies in the sector.
Unlike other sectors, a vital part of a healthcare company’s value lies not on the balance sheet, but in intangible elements. Relationships with the clinical staff, the maintenance of contracts with health insurers, and reputation among patients are assets that are extremely sensitive to changes in control.
If these elements are not protected by tailor-made contractual mechanisms, the investor runs the risk of paying for a value that deteriorates rapidly after the deal closes.
In healthcare, assets have “legs”: in specialty clinics, it is not uncommon for up to 50% of revenue to depend on just two or three doctors. Without long-term retention and alignment strategies, the departure of a single professional can jeopardize the facility’s revenue and accreditations.
Currently, what we see is that the era of large hospital networks and laboratories focused solely on scale has given way to a more selective and operational phase. Today, windows of opportunity shine on three main fronts:
- Specialty platforms: oncology, ophthalmology, genetics, etc.
- Regional operators: solid assets with a strong local presence, but which still lack institutionalization.
- “Asset-Light” models: outpatient care and home care.
Value creation in these assets rarely comes from multiple arbitrage. It stems from “grassroots” work: standardization of clinical protocols, efficiency gains, and governance that the asset — often family-owned — has never had.
The Maze of Regulatory Issues
One of the most overlooked issues, even by experienced investors, is the complexity of Brazilian regulations. There is an overlap of federal, state, and municipal rules that often contradict one another.
Effective due diligence in the sector must be meticulous, identifying everything from expired licenses and discrepancies between actual and authorized activities to corporate structures set up to meet the requirements of professional councils. These are common findings, and any one of them can directly impact the structure and price of the transaction. Due diligence that does not address sector-specific issues tends to lead to post-closing surprises, including price adjustment disputes and the triggering of indemnification clauses that could have been avoided.
Added to this is the challenge of information security. The handling of sensitive patient data requires not only compliance with the LGPD, but also a cybersecurity infrastructure that smaller assets often lack.
Identifying systemic vulnerabilities is crucial, as the reputational damage and penalties resulting from a data breach can devastate the asset’s value. Data protection has become a critical sustainability factor that directly impacts the exit multiple.
Furthermore, Brazil is not a homogeneous market. Assuming that administrative synergies will automatically materialize between assets in different regions is a common misconception. Cultural differences, distinct compensation structures, and the level of reliance on local contracts with operators can make integration significantly more expensive and slower than the financial model anticipated.
How to Exit the Asset?
Currently, the biggest challenge may not be entry, but exit. With more selective IPOs and strategic buyers adopting greater discipline in capital allocation, the divestment strategy must be built from day one. This directly impacts the negotiation of documents, resulting in shareholder agreements with more detailed governance structures, strengthened veto rights, and sophisticated drag-along and tag-along mechanisms. When poorly calibrated, these mechanisms can stall the transaction for years. It is no coincidence that the quality of the documentation negotiated at the outset is increasingly the determining factor in making an exit viable — or unviable.
Investors who ignore these “real-world” challenges and blindly trust theoretical efficiency models discover, too late, that part of the projected value does not materialize. Success belongs to those who have the discipline to price not only what the company is, but the real cost of what it needs to become.
Subscribe for free to JOTA’s Latest News newsletter and receive the day’s top legal and political news in your inbox.
The healthcare sector in Brazil remains one of the most attractive for investors, and there is still significant room for consolidation. But the gap between a successful investment and a disappointing outcome is rarely explained by the thesis. It almost always comes down to execution: conducting due diligence and calibrating contractual protection mechanisms.
Understanding the sector’s unique characteristics — from medical autonomy to the protection of sensitive data — is what enables the transformation of a given asset into a sustainable and profitable healthcare platform. In the current landscape, capital is more disciplined, and success belongs to those who know how to navigate the complexities between clinical care and legal and financial efficiency.
Article originally published in Portuguese in JOTA.